Premium
The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board
Author(s) -
Schmidt Mark E.,
Siemers Eric,
Snyder Peter J.,
Potter William Z.,
Cole Patricia,
Soares Holly
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.03.010
Subject(s) - deliverable , advisory committee , neuroimaging , foundation (evidence) , intellectual property , business , public relations , psychology , political science , management , neuroscience , economics , public administration , law
The Industry Scientific Advisory Board (ISAB) consists of representatives from the private companies and nonprofit foundations participating as sponsors of Alzheimer's Disease Neuroimaging Initiative (ADNI). Currently 21 companies are represented including pharmaceutical, imaging, and biotech concerns, and two foundations including the Alzheimer's Association. ISAB members meet regularly by teleconference or face‐to‐face at ADNI meetings and participate in the ADNI Core groups, all administered and organized by the Foundation for the National Institutes of Health. ISAB ‘deliverables' include dissemination of information to sponsors, assisting in scientific review of protocols and results, initiation and consideration of “add‐on” studies and analyses, and generation of consensus positions on industry priorities and concerns. Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression.